In clinical studies, SPECT imaging with 111In-trastuzumab and PET imaging with both 64Cu-trastuzumab and 89Zr-trastuzumab have shown lower rates of tumour detection in patients with advanced HER2-positive breast cancer than conventional imaging, including CT [12–14]. This evidence concerns the gene ERBB2 and neoplasm.